

# **Quantikine® ELISA**

# Human ICAM-1/CD54 Allele-specific Immunoassay

Catalog Number DCD540 SCD540 PDCD540

For the quantitative determination of human soluble Intercellular Adhesion Molecule 1 (ICAM-1) concentrations in cell culture supernates, serum, and plasma.\*

This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures.

<sup>\*</sup>A polymorphism exists in the human ICAM-1 sequence. The detection antibody used in this kit is allele-specific. It recognizes only the wild type ICAM-1 and does not detect the K29M, Kilifi mutation, ICAM-1. The Kilifi mutation variant is present in people of native-African descent at a frequency reported as high as 20% and predisposes to cerebral malaria (Fernandez-Reyes, D. et al. (1997) Hum. Mol. Genet. **6**:1357).

# **TABLE OF CONTENTS**

| SECTION                                 | PAGE |
|---|------|
| INTRODUCTION                            | 1    |
| PRINCIPLE OF THE ASSAY                  | 2    |
| LIMITATIONS OF THE PROCEDURE            | 2    |
| TECHNICAL HINTS                         | 2    |
| MATERIALS PROVIDED & STORAGE CONDITIONS | 3    |
| PHARMPAK CONTENTS                       | 4    |
| OTHER SUPPLIES REQUIRED                 | 5    |
| PRECAUTIONS                             |      |
| SAMPLE COLLECTION & STORAGE             | 5    |
| SAMPLE PREPARATION                      | 5    |
| REAGENT PREPARATION                     |      |
| ASSAY PROCEDURE                         | 7    |
| CALCULATION OF RESULTS                  |      |
| TYPICAL DATA                            |      |
| PRECISION                               |      |
| RECOVERY                                |      |
| LINEARITY                               |      |
| SENSITIVITY                             |      |
| CALIBRATION                             |      |
| SAMPLE VALUES                           |      |
| SPECIFICITY                             |      |
| REFERENCES                              |      |
| PLATE LAYOUT                            | 13   |

#### Manufactured and Distributed by:

#### **USA** R&D Systems, Inc.

614 McKinley Place NE, Minneapolis, MN 55413

TEL: 800 343 7475 612 379 2956

**FAX:** 612 656 4400

E-MAIL: info@bio-techne.com

#### Distributed by:

#### **Europe | Middle East | Africa** Bio-Techne Ltd.

19 Barton Lane, Abingdon Science Park

Abingdon OX14 3NB, UK TEL: +44 (0)1235 529449 FAX: +44 (0)1235 533420

E-MAIL: info.emea@bio-techne.com

#### China Bio-Techne China Co., Ltd.

Unit 1901, Tower 3, Raffles City Changning Office, 1193 Changning Road, Shanghai PRC 200051 **TEL:** +86 (21) 52380373 (400) 821-3475

FAX: +86 (21) 52371001

E-MAIL: info.cn@bio-techne.com

#### INTRODUCTION

Intercellular Adhesion Molecule 1 (ICAM-1), also known as CD54, is a nearly ubiquitous transmembrane glycoprotein that plays a key role in leukocyte migration and activation (1, 2). Human ICAM-1 contains five Ig-like domains in its extracellular domain (ECD) and associates into non-covalently linked dimers (3, 4). Soluble forms of monomeric and dimeric ICAM-1 (sICAM-1) can be generated via proteolytic cleavage by cathepsin G, elastase, MMP-9, MMP-14/MT1-MMP, and TACE/ADAM17 (5-8). In the mouse, alternate splicing generates isoforms that lack particular Ig-like domains and are differentially sensitive to proteolysis (5). Within the ECD, human ICAM-1 shares 53% amino acid sequence identity with mouse and rat ICAM-1.

The principal binding partners of ICAM-1 are the leukocyte integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) (9-11). The multivalency of dimeric ICAM-1 increases its strength of interaction with LFA-1 (9, 10). ICAM-1 also binds several non-integrin ligands including CD43/sialophorin, fibrinogen, hyaluronan, rhinoviruses, and *Plasmodium falciparum*-infected erythrocytes (12-16). At sites of inflammation, ICAM-1 is upregulated on endothelial and epithelial cells where it mediates the adhesion and paracellular migration of leukocytes expressing activated LFA-1 and Mac-1 (17-20). ICAM-1 ligation prolongs antigen presentation by dendritic cells and promotes T cell proliferation and cytokine release (21-23). ICAM-1 activation also participates in angiogenesis, wound healing, and bone metabolism (24-26).

Soluble ICAM-1 has been reported in serum, cerebrospinal fluid, urine, and bronchoalveolar lavage fluid (2, 27-31). Elevated levels of sICAM-1 in these fluids are associated with cardiovascular disease, type 2 diabetes, organ transplant dysfunction, oxidative stress, abdominal fat mass, hypertension, liver disease, and certain malignancies (32-40). sICAM-1 promotes angiogenesis and serves as an indicator of vascular endothelial cell activation or damage (41, 42). It also functions as an inhibitor of transmembrane ICAM-1 mediated activities such as monocyte adhesion to activated endothelial cells and sensitivity of tumor cells to NK cell-mediated lysis (7, 8).

The Quantikine® Human ICAM-1/CD54 Allele-specific Immunoassay is a 2.0 hour solid phase ELISA designed to measure human ICAM-1 in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human ICAM-1 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human ICAM-1 showed linear curves that were parallel to the standard curves obtained using the Quantikine® kit standards. These results indicate that this kit can be used to determine relative mass values for natural human ICAM-1.

#### PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for wild type human ICAM-1 has been pre-coated onto a microplate. Standards, controls, samples and conjugate are pipetted into the wells and any ICAM-1 present is sandwiched by the immobilized antibody and the enzyme-linked monoclonal antibody specific for human wild type ICAM-1. Following a wash to remove any unbound substances and/or antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of ICAM-1 bound. The color development is stopped and the intensity of the color is measured.

#### **LIMITATIONS OF THE PROCEDURE**

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
- The kit should not be used beyond the expiration date on the kit label.
- Do not mix or substitute reagents with those from other lots or sources.
- If samples generate values higher than the highest standard, further dilute the samples with the calibrator diluent and repeat the assay.
- Any variation in diluent, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.
- Variations in sample collection, processing, and storage may cause sample value differences.
- This assay is designed to eliminate interference by other factors present in biological samples. Until all factors have been tested in the Quantikine® Immunoassay, the possibility of interference cannot be excluded.

#### **TECHNICAL HINTS**

- When mixing or reconstituting protein solutions, always avoid foaming.
- To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer, and/or rotating the plate 180 degrees between wash steps may improve assay precision.
- Substrate Solution should remain colorless until added to the plate. Keep Substrate Solution protected from light. Substrate Solution should change from colorless to gradations of blue.
- Stop Solution should be added to the plate in the same order as the Substrate Solution. The color developed in the wells will turn from blue to yellow upon addition of the Stop Solution. Wells that are green in color indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution.

# **MATERIALS PROVIDED & STORAGE CONDITIONS**

Store the unopened kit at 2-8 °C. Do not use past kit expiration date.

| PART                        | PART#  | CATALOG #<br>DCD540 | CATALOG #<br>SCD540 | DESCRIPTION  | STORAGE OF OPENED/<br>RECONSTITUTED MATERIAL   |
|-----------------------------|--------|---------------------|---------------------|--|--|
| Human ICAM-1<br>Microplate  | 893602 | 1 plate             | 6 plates            | 96 well polystyrene microplate (12 strips of 8 wells) coated with a monoclonal antibody specific for human wild type and variant ICAM-1. | Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of zip-seal. May be stored for up to 1 month at 2-8 °C.* |
| Human ICAM-1<br>Conjugate   | 893603 | 1 vial              | 6 vials             | 12 mL/vial of a monoclonal antibody specific for human wild type ICAM-1 conjugated to horseradish peroxidase with preservatives.         |  |
| Human ICAM-1<br>Standard    | 893604 | 1 vial              | 6 vials             | Recombinant human ICAM-1 in a buffer with preservatives; lyophilized. <i>Refer to the vial label for reconstitution volume</i> .         |  |
| Calibrator Diluent<br>RD5-7 | 895045 | 1 vial              | 6 vials             | 21 mL/vial of a buffered protein base with preservatives.  | May be stored for up to 1 month at 2-8 °C.*  |
| Wash Buffer<br>Concentrate  | 895003 | 1 vial              | 6 vials             | 21 mL/vial of a 25-fold concentrated solution of buffered surfactant with preservative.  May turn yellow over time.                      |  |
| Color Reagent A             | 895000 | 1 vial              | 6 vials             | 12 mL/vial of stabilized hydrogen peroxide.  |  |
| Color Reagent B             | 895001 | 1 vial              | 6 vials             | 12 mL/vial of stabilized chromogen (tetramethylbenzidine).   |  |
| Stop Solution               | 895032 | 1 vial              | 6 vials             | 6 mL/vial of 2 N sulfuric acid.  |  |
| Plate Sealers               | N/A    | 4 strips            | 24 strips           | Adhesive strips.   |  |

<sup>\*</sup> Provided this is within the expiration date of the kit.

DCD540 contains sufficient materials to run an ELISA on one 96 well plate. SCD540 (SixPak) contains sufficient materials to run ELISAs on six 96 well plates.

This kit is also available in a PharmPak (R&D Systems®, Catalog # PDCD540). Specific vial counts of each component may vary. Refer to the PharmPak Contents section for specific vial counts.

#### PHARMPAK CONTENTS

Each PharmPak contains reagents sufficient for the assay of 50 microplates (96 wells/plate). The package inserts supplied are the same as those supplied in the single kit packs and because of this, a few minor differences related to the number of reagents and their container sizes should be noted.

- Sufficient material is supplied to perform at least 50 standard curves; reuse of each vial may be required. The number of vials, and the number of standard curves obtained per vial will vary with the analyte.
- Wash Buffer 25X Concentrate is bulk packed in 125 mL bottles containing 100 mL. **Note:** Additional wash buffer is available for purchase (R&D Systems®, Catalog # WA126).

The reagents provided in this PharmPak are detailed below.

| PART                         | PART # | QUANTITY   |
|------------------------------|--------|------------|
| Human ICAM-1 Microplate      | 893602 | 50 plates  |
| Human ICAM-1 Conjugate       | 893603 | 50 vials   |
| Human ICAM-1 Standard        | 893604 | 25 vials   |
| Calibrator Diluent RD5-7     | 895045 | 50 vials   |
| Color Reagent A              | 895000 | 50 vials   |
| Color Reagent B              | 895001 | 50 vials   |
| Wash Buffer Concentrate, 25X | 895126 | 9 bottles  |
| Stop Solution                | 895032 | 50 vials   |
| Plate Sealers                | N/A    | 100 sheets |
| Package Insert               | 751906 | 2 booklets |

# **OTHER SUPPLIES REQUIRED**

- Microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
- Pipettes and pipette tips.
- Deionized or distilled water.
- Squirt bottle, manifold dispenser, or automated microplate washer.
- 500 mL graduated cylinder.
- Horizontal orbital microplate shaker (0.12" orbit) capable of maintaining a speed of  $500 \pm 50$  rpm.
- Test tubes for dilution of standards and samples.
- Human ICAM-1 Controls (optional; R&D Systems®, Catalog # QC236).

#### **PRECAUTIONS**

The Stop Solution provided with this kit is an acid solution.

Some components in this kit contain a preservative which may cause an allergic skin reaction. Avoid breathing mist.

Color Reagent B may cause skin, eye, and respiratory irritation. Avoid breathing fumes.

Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling. Refer to the SDS on our website prior to use.

#### SAMPLE COLLECTION & STORAGE

The sample collection and storage conditions listed below are intended as general guidelines. Sample stability has not been evaluated.

**Cell Culture Supernates** - Remove particulates by centrifugation and assay immediately or aliquot and store samples at  $\leq$  -20 °C. Avoid repeated freeze-thaw cycles.

**Serum** - Use a serum separator tube (SST) and allow samples to clot for 30 minutes at room temperature before centrifugation for 15 minutes at 1000 x g. Remove serum and assay immediately or aliquot and store samples at  $\leq$  -20 °C. Avoid repeated freeze-thaw cycles.

**Plasma** - Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store samples at  $\leq$  -20 °C. Avoid repeated freeze-thaw cycles.

**Note:** Citrate plasma has not been validated for use in this assay.

### **SAMPLE PREPARATION**

Serum and plasma samples require a 20-fold dilution. A suggested 20-fold dilution is 20  $\mu$ L of sample + 380  $\mu$ L of Calibrator Diluent RD5-7.

#### REAGENT PREPARATION


Bring all reagents to room temperature before use.

**Wash Buffer** - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 20 mL of Wash Buffer Concentrate to 480 mL of deionized or distilled water to prepare 500 mL of Wash Buffer.

**Substrate Solution** - Color Reagents A and B should be mixed together in equal volumes within 15 minutes of use. Protect from light. 200 µL of the resultant mixture is required per well.

**Human ICAM-1 Standard** - **Refer to the vial label for reconstitution volume.** Reconstitute the Human ICAM-1 Standard with deionized or distilled water. This reconstitution produces a stock solution of 250 ng/mL. Mix the standard to ensure complete reconstitution and allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions.

Pipette 800  $\mu$ L of Calibrator Diluent RD5-7 into the 50 ng/mL tube. Pipette 500  $\mu$ L into the remaining tubes. Use the stock solution to produce a dilution series (below). Mix each tube thoroughly before the next transfer. The 50 ng/mL standard serves as the high standard. Calibrator Diluent RD5-7 serves as the zero standard (0 ng/mL).



#### **ASSAY PROCEDURE**

Bring all reagents and samples to room temperature before use. It is recommended that all standards, controls, and samples be assayed in duplicate.

- 1. Prepare all reagents, working standards, and samples as directed in the previous sections.
- 2. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
- 3. Add 100 µL of Human ICAM-1 Conjugate to each well.
- 4. Add 100  $\mu$ L of standard, control, or sample\* per well. Cover with the adhesive strip provided. Incubate for 1.5 hours at room temperature on a horizontal orbital microplate shaker (0.12" orbit) set at 500  $\pm$  50 rpm. A plate layout is provided to record standards and samples assayed.
- 5. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (400 µL) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
- 6. Add 200  $\mu$ L of Substrate Solution to each well. Incubate for 30 minutes at room temperature **on the bench top. Protect from light.**
- 7. Add 50  $\mu$ L of Stop Solution to each well. The color in the wells should change from blue to yellow. If the color in the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.
- 8. Determine the optical density of each well within 30 minutes, using a microplate reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

<sup>\*</sup>Samples may require dilution. See Sample Preparation section.

#### CALCULATION OF RESULTS


Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density (O.D.).

Create a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the human ICAM-1 concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data.

If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

#### TYPICAL DATA

This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.



| 0.D.  | Average   | Corrected   |
|-------|---|---|
| 0.008 | 0.010   | _   |
| 0.011 |   |   |
| 0.037 | 0.039   | 0.029   |
| 0.041 |   |   |
| 0.082 | 0.083   | 0.073   |
| 0.084 |   |   |
| 0.196 | 0.197   | 0.187   |
| 0.198 |   |   |
| 0.475 | 0.484   | 0.474   |
| 0.492 |   |   |
| 1.095 | 1.106   | 1.096   |
| 1.116 |   |   |
| 2.062 | 2.081   | 2.071   |
| 2.100 |   |   |
|       | 0.008<br>0.011<br>0.037<br>0.041<br>0.082<br>0.084<br>0.196<br>0.198<br>0.475<br>0.492<br>1.095<br>1.116<br>2.062 | 0.008     0.010       0.011     0.037       0.041     0.082       0.084     0.196       0.198     0.475       0.492     0.484       1.095     1.106       1.116     2.062       2.081 |

# **PRECISION**

# **Intra-Assay Precision** (Precision within an assay)

Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

# Inter-Assay Precision (Precision between assays)

Three samples of known concentration were tested in forty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.

|                    | Intra-Assay Precision |      |      | Inter-Assay Precision |      |      |
|--------------------|-----------------------|------|------|-----------------------|------|------|
| Sample             | 1 2 3                 |      |      | 1                     | 2    | 3    |
| n                  | 20                    | 20   | 20   | 40                    | 40   | 40   |
| Mean (ng/mL)       | 4.61                  | 12.1 | 19.6 | 4.77                  | 12.5 | 20.5 |
| Standard deviation | 0.17                  | 0.63 | 0.98 | 0.32                  | 0.67 | 0.90 |
| CV (%)             | 3.7                   | 5.2  | 5.0  | 6.7                   | 5.4  | 4.4  |

# **RECOVERY**

The recovery of human ICAM-1 spiked to levels throughout the range of the assay was evaluated.

| Sample Type Average % Recovery |     | Range   |
|--------------------------------|-----|---------|
| Cell culture media (n=5)       | 104 | 90-109% |

# **LINEARITY**

To assess the linearity of the assay, samples spiked with or containing high concentrations of human ICAM-1 were serially diluted with calibrator diluent to produce samples with values within the dynamic range of the assay.

|     |                       | Cell culture<br>media<br>(n=4) | Serum*<br>(n=4) | EDTA plasma* (n=4) | Heparin<br>plasma*<br>(n=4) |
|-----|-----------------------|--------------------------------|-----------------|--------------------|-----------------------------|
| 1.2 | Average % of Expected | 97                             | 101             | 105                | 100                         |
| 1:2 | Range (%)             | 94-101                         | 97-103          | 104-108            | 95-104                      |
| 1.4 | Average % of Expected | 99                             | 102             | 104                | 101                         |
| 1:4 | Range (%)             | 96-106                         | 99-104          | 101-106            | 90-109                      |
| 1.0 | Average % of Expected | 95                             | 99              | 100                | 104                         |
| 1:8 | Range (%)             | 92-98                          | 92-108          | 94-105             | 99-107                      |

<sup>\*</sup>Samples were diluted prior to assay as directed in the Sample Preparation section.

#### **SENSITIVITY**

Forty-six assays were evaluated and the minimum detectable dose (MDD) of human ICAM-1 ranged from 0.049-0.254 ng/mL. The mean MDD was 0.096 ng/mL.

The MDD was determined by adding two standard deviations to the mean O.D. value of twenty zero standard replicates and calculating the corresponding concentration.

#### **CALIBRATION**

This immunoassay is calibrated against a highly purified NSO-expressed recombinant human ICAM-1 produced at R&D Systems®.

#### SAMPLE VALUES

**Serum/Plasma** - Samples from apparently healthy volunteers were evaluated for the presence of human ICAM-1 in this assay. No medical histories were available for the donors used in this study.

| Sample Type           | Mean (ng/mL) | Range (ng/mL) | Standard Deviation (ng/mL) |
|-----------------------|--------------|---------------|----------------------------|
| Serum (n=54)          | 208          | 98.8-320      | 40.7                       |
| EDTA plasma (n=54)    | 211          | 100-307       | 42.9                       |
| Heparin plasma (n=54) | 204          | 106-337       | 41.6                       |

**Cell Culture Supernates** - Human peripheral blood cells (1 x 10 $^6$  cells/mL) were cultured in DMEM supplemented with 5% fetal bovine serum, 50  $\mu$ M  $\beta$ -mercaptoethanol, 2 mM L-glutamine, 100 U/mL penicillin, and 100  $\mu$ g/mL streptomycin sulfate. Cells were cultured unstimulated or stimulated with 10  $\mu$ g/mL PHA. Aliquots of the cell culture supernate were removed and assayed for human ICAM-1. No detectable levels were observed.

# **SPECIFICITY**

ICAM-2

This assay recognizes natural and recombinant human ICAM-1.

The factors listed below were prepared at 50 ng/mL in calibrator diluent and assayed for cross-reactivity. Preparations of the following factors at 50 ng/mL in a mid-range recombinant human ICAM-1 control were assayed for interference. No significant cross-reactivity or interference was observed.

| Recombinant human: |             | Recombinant mouse: | Recombinant rat: |
|--------------------|-------------|--------------------|------------------|
| ALCAM              | ICAM-3      | ALCAM              | ICAM-1           |
| BCAM               | ICAM-5      | CHL-1              | E-Selectin       |
| Cadherin-8         | JAM-A       | E-Cadherin         | L-Selectin       |
| Cadherin-11        | JAM-B       | Endocan            | MAG              |
| CD31/PECAM-1       | JAM-C       | E-Selectin         |                  |
| CHL-1              | LOX-1       | Galectin-1         |                  |
| Contactin-1        | L-Selectin  | Galectin-3         |                  |
| Contactin-2        | MCAM        | Galectin-7         |                  |
| Contactin-4        | N-Cadherin  | ICAM-1             |                  |
| DC-SIGNR           | NCAM-1      | ICAM-2             |                  |
| Desmoglein-1       | NrCAM       | ICAM-5             |                  |
| Desmoglein-2       | P-Cadherin  | JAM-A              |                  |
| DNAM-1             | P-Selectin  | JAM-B              |                  |
| E-Cadherin         | Siglec-2    | JAM-C              |                  |
| Endocan            | Siglec-3    | LOX-1              |                  |
| EpCAM              | Siglec-5    | L-Selectin         |                  |
| E-Selectin         | Siglec-6    | MAdCAM-1           |                  |
| Galectin-1         | Siglec-7    | P-Cadherin         |                  |
| Galectin-2         | Siglec-9    | P-Selectin         |                  |
| Galectin-3         | Siglec-10   | Siglec-F           |                  |
| Galectin-4         | TROP-2      | VCAM-1             |                  |
| Galectin-7         | VCAM-1      |                    |                  |
| Galectin-8         | VE-Cadherin |                    |                  |
|                    |             |                    |                  |


This assay does not recognize a natural variant of intercellular adhesion molecule-1 (ICAM-1<sup>Kilifi</sup>). This polymorphism at K29/M in the N-terminal domain of ICAM-1 is present in African-Americans at a frequency reported as high as 20% and predisposes to cerebral malaria (43-45). An internal study of 30 African-American samples found only one sample (3.3%) non-detectable.


#### **REFERENCES**

- 1. Hogg, N. et al. (1991) Chem. Immunol. **50**:98.
- 2. Witkowska, A.M. and M.H. Borawska (2004) Eur. Cytokine Netw. 15:91.
- 3. Staunton, D.E. et al. (1988) Cell 52:925.
- 4. Reilly, P.L. et al. (1995) J. Immunol. **155**:529.
- 5. Robledo, O. et al. (2003) Eur. J. Immunol. **33**:1351.
- 6. Sithu, S.D. et al. (2007) J. Biol. Chem. 282:25010.
- 7. Fiore, E. et al. (2002) Oncogene **21**:5213.
- 8. Tsakadze, N.L. et al. (2006) J. Biol. Chem. 281:3157.
- 9. Jun, C.D. et al. (2001) Proc. Natl. Acad. Sci. USA 98:6830.
- 10. Miller, J. et al. (1995) J. Exp. Med. **182**:1231.
- 11. Diamond, M.S. et al. (1990) J. Cell Biol. **111**:3129.
- 12. Rosenstein, Y. et al. (1991) Nature **354**:233.
- 13. Pluskota, E. and S.E. D'Souza (2000) Eur. J. Biochem. **267**:4693.
- 14. McCourt, P.A.G. et al. (1994) J. Biol. Chem. **269**:30081.
- 15. Kirchberger, S. et al. (2006) Immunobiology **211**:537.
- 16. Chakravorty S.J. and A. Craig (2005) Eur J. Cell Biol. 84:15.
- 17. Dietrich, J.B. (2002) J. Neuroimmunol. 128:58.
- 18. Humlicek, A.L. et al. (2004) Am. J. Pysiol. Lung Cell Mol. Physiol. 287:L598.
- 19. Steeber, D.A. et al. (1999) J. Immunol. **163**:2176.
- 20. Forbes, E. et al. (2006) J. Leukoc. Biol. 80:330.
- 21. Lebedeva, T. et al. (2005) Curr. Opin. Immunol. 17:251.
- 22. Chirathaworn, C. et al. (2002) J. Immunol. 168:5530.
- 23. Camacho, S.A. et al. (2001) Nat. Immunol. 2:523.
- 24. Langston, W. et al. (2007) Free Rad. Biol. Med. 42:720.
- 25. Yukami, T. et al. (2007) J. Leukoc. Biol. 82:519.
- 26. Lavigne, P. et al. (2005) Expert Opin. Biol. Ther. **5**:313.
- 27. Rothlein, R. et al. (1991) J. Immunol. **147**:3788.
- 28. Jander, S. et al. (1993) Neurology **43**:1809.
- 29. Shijubo, N. et al. (1994) Clin. Exp. Immunol. 95:156.
- 30. Teppo, A.M. *et al.* (2001) Transplantation **71**:1113.
- 31. Melis, M. et al. (2003) Am. J. Respir. Crit. Care Med. **167**:1131.
- 32. Benson, V. et al. (2007) Curr. Mol. Med. 7:219.
- 33. Hoogeveen, R.C. et al. (2007) Diabetologia **50**:36.
- 34. Covarrubias, M. et al. (2007) Am. J. Transplant. **7**:2573.
- 35. Cottone, S. et al. (2007) J. Hypertens. **25**:423.
- 36. Brake, D.K. et al. (2006) Am. J. Physiol. Cell Physiol. 291:C1232.
- 37. Madej, A. et al. (2005) Pharmacol. Rep. **57**:878.
- 38. El-Gohary, A.M. et al. (2004) Egypt. J. Immunol. 11:109.
- 39. Christiansen, I. et al. (1996) Br. J. Haematol. 92:639.
- 40. Kang, X. et al. (2005) World J. Gastroenterol. 11:4250.
- 41. Gho, Y.S. et al. (1999) Cancer Res. **59**:5128.
- 42. Constans, J. and C. Conri (2006) Clin. Chim. Acta 368:33.
- 43. Register, T.C. et al. (2004) Clinical Chemistry 50:11.
- 44. Craig, A. et al. (2000) Human Molecular Genetics 9:525.
- 45. Fernandez-Reyes, D. (1997) Human Molecular Genetics 6:1357.

# **PLATE LAYOUT**

Use this plate layout to record standards and samples assayed.





All trademarks and registered trademarks are the property of their respective owners.

©2019 R&D Systems®, Inc.